Torthaí cuardaigh - Jesse M. Cedarbaum

Beachtaigh na torthaí
  1. 1
    Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

    Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic de réir S. Pablo Sardi, Jesse M. Cedarbaum, Patrik Brundin

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Voice of the patient: Emergence of new motor and non-motor symptoms in early Parkinson’s Disease?

    Voice of the patient: Emergence of new motor and non-motor symptoms in early Parkinson’s Disease? de réir Michelle Hyczy de Siqueira Tosin, Tanya Simuni, Glenn T. Stebbins, Jesse M. Cedarbaum

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Pré-impressão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?

    Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease? de réir Michelle Hyczy de Siqueira Tosin, Tanya Simuni, Glenn T. Stebbins, Jesse M. Cedarbaum

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans

    Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans de réir Bernard Coulie, Lawrence A. Szarka, Michael Camilleri, Duane D. Burton, Sanna McKinzie, Nancy Stambler, Jesse M. Cedarbaum

    Foilsithe / Cruthaithe 2000
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Considerations to address missing data when deriving clinical trial endpoints from digital health technologies

    Considerations to address missing data when deriving clinical trial endpoints from digital health technologies de réir Junrui Di, Charmaine Demanuele, Anna Kettermann, F. Işık Karahanoğlu, Joseph C. Cappelleri, Andrew Potter, Denise Bury, Jesse M. Cedarbaum, Bill Byrom

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Neuropsychiatric symptoms in Alzheimer's disease

    Neuropsychiatric symptoms in Alzheimer's disease de réir Constantine G. Lyketsos, María C. Carrillo, J. Michael Ryan, Ara S. Khachaturian, Paula T. Trzepacz, Joan Amatniek, Jesse M. Cedarbaum, Robert Brashear, David S. Miller

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán
    Editorial
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker

    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker de réir Rahul Gaurav, Lydia Yahia-Chérif, Nadya Pyatigorskaya, Graziella Mangone, Emma Biondetti, Romain Valabrègue, Claire Ewenczyk, R. Matthew Hutchison, Jesse M. Cedarbaum, Jean‐Christophe Corvol, Marie Vidailhet, Stéphane Lehericy

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

    Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors de réir William P. Tew, Michael S. Gordon, John R. Murren, Jakob Dupont, S. Pezzulli, Carol Aghajanian, Paul Sabbatini, David S. Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease

    FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease de réir Dawn C. Matthews, Hedva Lerman, Ana Lukić, Randolph D. Andrews, Anat Mirelman, Miles N. Wernick, Nir Giladi, Stephen C. Strother, Karleyton C. Evans, Jesse M. Cedarbaum, Einat Even‐Sapir

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders

    Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders de réir Isabel Schulz, Niels Kruse, Roland G. Gera, Thomas Kremer, Jesse M. Cedarbaum, Robin Barbour, Wagner Zago, Sebastian Schade, Birgit Otte, Michael Bartl, Samantha J. Hutten, Claudia Trenkwalder, Brit Mollenhauer

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research

    Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research de réir Reham Badawy, Farhan Hameed, Lauren Bataille, Max A. Little, Kasper Claes, Suchi Saria, Jesse M. Cedarbaum, Diane Stephenson, Jon Neville, Walter Maetzler, Alberto J. Espay, Bastiaan R. Bloem, Tanya Simuni, Daniel R. Karlin

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein

    A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein de réir Kalpana Merchant, Jesse M. Cedarbaum, Patrik Brundin, Kuldip D. Dave, Jamie L. Eberling, Alberto J. Espay, Samantha J. Hutten, Monica Javidnia, Johan Luthman, Walter Maetzler, Liliana Menalled, Alyssa Reimer, A. Jon Stoessl, David M. Weiner

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

    Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials de réir Michael Gold, Joan Amatniek, María C. Carrillo, Jesse M. Cedarbaum, James A. Hendrix, Bradley B. Miller, Julie M. Robillard, John Jeremy Rice, Holly Soares, Maria Tome, Ioannis Tarnanas, Gabriel Vargas, Lisa J. Bain, Sara J. Czaja

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    The effect of polygenic risk score on PD risk and phenotype in <i>LRRK2</i> G2019S and <i>GBA1</i> carriers

    The effect of polygenic risk score on PD risk and phenotype in <i>LRRK2</i> G2019S and <i>GBA1</i> carriers de réir Orly Goldstein, Shachar Shani, Mali Gana‐Weisz, Nadav Elkoshi, Fergal Casey, Yu Sun, Khyati Chandratre, Jesse M. Cedarbaum, Cornelis Blauwendraat, Anat Bar‐Shira, Avner Thaler, Tanya Gurevich, Anat Mirelman, Nir Giladi, Avi Orr‐Urtreger, Roy N. Alcalay

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

    A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease de réir Stephen Salloway, Reisa A. Sperling, Ron Keren, Anton P. Porsteinsson, C H van Dyck, Pierre N. Tariot, S. Gilman, Douglas L. Arnold, Susan Abushakra, C. Hernandez, Gerald Crans, E. Liang, Gráinne Quinn, Menghis Bairu, Aleksandra Pastrak, Jesse M. Cedarbaum

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

    Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 de réir Mirosław Bryś, Laura Fanning, Serena Hung, Aaron Ellenbogen, Natalia A. Penner, Minhua Yang, Mackenzie Welch, E. Koenig, Eric David, Tara Fox, Shavy Makh, Jason Aldred, Ira Goodman, Blake Pepinsky, Yuting Liu, Danielle Graham, Andreas Weihofen, Jesse M. Cedarbaum

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease

    Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease de réir Anat Mirelman, Inbar Hillel, Lynn Rochester, Silvia Del Din, Bastiaan R. Bloem, Laura Avanzino, Alice Nieuwboer, Inbal Maidan, Talia Herman, Avner Thaler, Tanya Gurevich, Meir Kestenbaum, Avi Orr‐Urtreger, Mirosław Bryś, Jesse M. Cedarbaum, Nir Giladi, Jeffrey M. Hausdorff

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Digital Mobility Measures: A Window into Real‐World Severity and Progression of Parkinson's Disease

    Digital Mobility Measures: A Window into Real‐World Severity and Progression of Parkinson's Disease de réir Anat Mirelman, Jana Volkov, Amit Salomon, Eran Gazit, Alice Nieuwboer, Lynn Rochester, Silvia Del Din, Laura Avanzino, Elisa Pelosin, Bastiaan R. Bloem, Ugo Della Croce, Andrea Cereatti, Avner Thaler, Daniel Roggen, Claudia Mazzà, Julia Shirvan, Jesse M. Cedarbaum, Nir Giladi, Jeffrey M. Hausdorff

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients

    Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients de réir Amgad Droby, Avital Yoffe-Vasiliev, Dikla Atias, Kyle Fraser, Omar S. Mabrouk, Nurit Omer, Anat Bar‐Shira, Mali Gana‐Weisz, Orly Goldstein, Moran Artzi, Dafna Ben Bashat, Roy N. Alcalay, Avi Orr‐Urtreger, Julia Shirvan, Jesse M. Cedarbaum, Nir Giladi, Anat Mirelman, Avner Thaler

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models

    Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models de réir Andreas Weihofen, Yuting Liu, Joseph W. Arndt, Christian Huy, Chao Quan, Benjamin Smith, Jean-Luc Baeriswyl, Nicole Cavegn, Luzia Senn, Lihe Su, Galina Marsh, Pavan K. Auluck, Fabio Montrasio, Roger M. Nitsch, Warren D. Hirst, Jesse M. Cedarbaum, R. Blake Pepinsky, Jan Grimm, Paul H. Weinreb

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: